Page last updated: 2024-08-24

atorvastatin and Colitis, Granulomatous

atorvastatin has been researched along with Colitis, Granulomatous in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bredberg, A; Grip, O; Janciauskiene, S	1
Grip, O; Janciauskiene, S	1
Grip, O; Janciauskiene, S; Lindgren, S	1

Trials

1 trial(s) available for atorvastatin and Colitis, Granulomatous

Article	Year
Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. British journal of pharmacology, 2008, Volume: 155, Issue:7 Topics: Adult; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Chemokine CCL8; Crohn Disease; CX3C Chemokine Receptor 1; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Leukocyte L1 Antigen Complex; Lipopolysaccharide Receptors; Male; Monocytes; Pyrroles; Receptors, CCR2; Receptors, Chemokine; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Tumor Necrosis Factor-alpha; Young Adult	2008

Article

Year

Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.

British journal of pharmacology, 2008, Volume: 155, Issue:7

Topics: Adult; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Chemokine CCL8; Crohn Disease; CX3C Chemokine Receptor 1; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Leukocyte L1 Antigen Complex; Lipopolysaccharide Receptors; Male; Monocytes; Pyrroles; Receptors, CCR2; Receptors, Chemokine; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Tumor Necrosis Factor-alpha; Young Adult

2008

Other Studies

2 other study(ies) available for atorvastatin and Colitis, Granulomatous

Article	Year
Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PloS one, 2009, Volume: 4, Issue:5 Topics: Adult; Atorvastatin; C-Reactive Protein; Chemokine CXCL10; Crohn Disease; Cytokines; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Young Adult	2009
Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflammatory bowel diseases, 2004, Volume: 10, Issue:3 Topics: Adolescent; Adult; Atorvastatin; Biomarkers; Case-Control Studies; Chemokine CCL2; Crohn Disease; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophage Migration-Inhibitory Factors; Male; Middle Aged; Monocytes; Pyrroles; Tumor Necrosis Factor-alpha	2004

Article

Year

Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.

PloS one, 2009, Volume: 4, Issue:5

Topics: Adult; Atorvastatin; C-Reactive Protein; Chemokine CXCL10; Crohn Disease; Cytokines; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Young Adult

2009

Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.

Inflammatory bowel diseases, 2004, Volume: 10, Issue:3

Topics: Adolescent; Adult; Atorvastatin; Biomarkers; Case-Control Studies; Chemokine CCL2; Crohn Disease; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophage Migration-Inhibitory Factors; Male; Middle Aged; Monocytes; Pyrroles; Tumor Necrosis Factor-alpha

2004